X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs IPCA LABS - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE IPCA LABS CADILA HEALTHCARE/
IPCA LABS
 
P/E (TTM) x 18.4 28.6 64.1% View Chart
P/BV x 4.2 3.4 122.5% View Chart
Dividend Yield % 1.0 0.1 712.5%  

Financials

 CADILA HEALTHCARE   IPCA LABS
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
IPCA LABS
Mar-18
CADILA HEALTHCARE/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs558695 80.2%   
Low Rs362400 90.4%   
Sales per share (Unadj.) Rs116.3260.2 44.7%  
Earnings per share (Unadj.) Rs17.919.0 94.2%  
Cash flow per share (Unadj.) Rs23.133.1 70.0%  
Dividends per share (Unadj.) Rs3.501.00 350.0%  
Dividend yield (eoy) %0.80.2 417.0%  
Book value per share (Unadj.) Rs85.4213.0 40.1%  
Shares outstanding (eoy) m1,023.74126.20 811.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.02.1 187.8%   
Avg P/E ratio x25.728.9 89.1%  
P/CF ratio (eoy) x19.916.6 120.0%  
Price / Book Value ratio x5.42.6 209.4%  
Dividend payout %19.65.3 371.6%   
Avg Mkt Cap Rs m470,66469,120 680.9%   
No. of employees `00011.813.3 89.2%   
Total wages/salary Rs m18,5457,359 252.0%   
Avg. sales/employee Rs Th10,072.72,477.4 406.6%   
Avg. wages/employee Rs Th1,569.1555.2 282.6%   
Avg. net profit/employee Rs Th1,547.7180.6 856.8%   
INCOME DATA
Net Sales Rs m119,04932,836 362.6%  
Other income Rs m1,132418 270.8%   
Total revenues Rs m120,18133,254 361.4%   
Gross profit Rs m28,4754,505 632.1%  
Depreciation Rs m5,3881,777 303.2%   
Interest Rs m911240 379.3%   
Profit before tax Rs m23,3082,905 802.3%   
Minority Interest Rs m6280-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,644511 1,104.3%   
Profit after tax Rs m18,2922,394 764.0%  
Gross profit margin %23.913.7 174.3%  
Effective tax rate %24.217.6 137.6%   
Net profit margin %15.47.3 210.7%  
BALANCE SHEET DATA
Current assets Rs m82,00519,455 421.5%   
Current liabilities Rs m60,72010,076 602.6%   
Net working cap to sales %17.928.6 62.6%  
Current ratio x1.41.9 69.9%  
Inventory Days Days7398 74.7%  
Debtors Days Days9867 146.8%  
Net fixed assets Rs m83,70320,260 413.2%   
Share capital Rs m1,024252 405.7%   
"Free" reserves Rs m86,42126,633 324.5%   
Net worth Rs m87,44526,886 325.2%   
Long term debt Rs m25,5512,340 1,091.9%   
Total assets Rs m180,65341,173 438.8%  
Interest coverage x26.613.1 203.0%   
Debt to equity ratio x0.30.1 335.7%  
Sales to assets ratio x0.70.8 82.6%   
Return on assets %10.66.4 166.1%  
Return on equity %20.98.9 234.9%  
Return on capital %22.010.8 204.3%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m42,68315,642 272.9%   
Fx outflow Rs m11,2424,884 230.2%   
Net fx Rs m31,44110,759 292.2%   
CASH FLOW
From Operations Rs m9,1933,411 269.5%  
From Investments Rs m-9,737-1,354 719.1%  
From Financial Activity Rs m515-1,304 -39.5%  
Net Cashflow Rs m-29753 -3.9%  

Share Holding

Indian Promoters % 74.8 45.9 163.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 11.4 72.8%  
FIIs % 5.9 25.3 23.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 17.4 63.2%  
Shareholders   44,069 36,892 119.5%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   DR. REDDYS LAB  PIRAMAL ENTERPRISES  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  PFIZER  

Compare CADILA HEALTHCARE With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 331 Points Higher; Oil & Gas Stocks Witness Buying(Closing)

After opening on a negative note, share markets in India witnessed buying interest during closing hours and ended the day on a positive note.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of CADILA HEALTHCARE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)

Oct 31, 2018

The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Nov 13, 2018 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - GLENMARK PHARMA COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS